Insulet Corp at Raymond James Institutional Investors Conference Transcript
All right. Good morning. I think we'll start. Welcome to the 44th Annual Raymond James Institutional Investors Conference. My name is Jayson Bedford. I cover the medical technology sector here. It's really our pleasure to have with us the team from Insulet. Insulet has been a loyal participant in this conference for the last decade. And I think, I was looking back a decade ago, it was sub-$2 billion in market cap. So it's been a wonderful growth story over the years.
With us today, we have the company's CEO, Jim Hollingshead. We have the company's CFO, Wayde McMillan; and VP of IR, Deb Gordon. So with that, I'm going to hand it over to Jim.
Thanks, Jayson, and good morning, everybody. Thanks for coming today. Let me start by introducing you to Christian, who you see here on this slide. Christian is 9 years old. And if you look really closely, on
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
